Laboratory-embedded entrepreneurship program lead from Argonne National Laboratory Chain Reaction Innovations; eligibility, timing, and fit require current official verification.
No application or relationship exists. This record does not establish eligibility, availability, funding, recommendation, provider interest, or authorization to apply.
Provider
Argonne National Laboratory Chain Reaction Innovations
Kind
Laboratory-embedded entrepreneurship program
Status
forthcoming application window; not yet open
Timing
The Cohort 2027 application is scheduled to open September 15 and close October 30, 2026 at 5 p.m. on the official page. The current page still labels the application closed because the 2026 cohort window has ended.
Eligibility
The official page says preferred applicants are technical founders with hands-on laboratory experience developing an early-stage innovation and that applicants must be U.S. citizens or lawful permanent residents when applying. Four yes-or-no eligibility questions, the forthcoming 2027 application, online portal, FAQ, appointment, laboratory, intellectual-property, safety, conflict, and program rules control actual eligibility.
Access notes
CRI states that the two-year program includes a $115,000 annual stipend plus healthcare benefits, non-dilutive support, Argonne facilities and expertise, and business networks, and that Argonne and DOE take no startup equity. Those statements do not establish acceptance, total project funding, laboratory or equipment availability, intellectual-property terms, outside-work permissions, safety approval, incorporation needs, relocation, accessibility, or fit for a GShips product.
Official link checked
2026-07-26
Relationship
indexed only; no formal relationship
Potential fit and evidence boundary
Advanced materials, industrial efficiency, manufacturing digitization, advanced manufacturing, energy-water systems, computing, semiconductors, grids, storage, critical materials, recycling, buildings, scientific platforms, transport efficiency, and energy technology
Evidence boundary: Argonne's official application page supports the September 15–October 30, 2026 Cohort 2027 window, 5 p.m. close statement, U.S.-citizen or lawful-permanent-resident rule, preferred technical-founder profile, two-year duration, $115,000 annual stipend plus healthcare, stated non-dilutive support, no-equity statement, and listed priority areas. It does not establish application availability before September 15, a specific person's eligibility, acceptance, adequate funding, facility access, intellectual-property outcome, safety approval, accessibility, relocation, startup success, or relationship.
Task-specific matches
No bounded task match is recorded.
Proposed founder action—not undertaken
Before the window opens, prepare only a no-application fit memo for a genuinely laboratory-dependent Earth-first technology, comparing CRI with non-laboratory and non-venture alternatives. Do not pre-apply, nominate, contact staff, incorporate, disclose confidential material, or imply Argonne or DOE support without separate authorization and independent eligibility, technical, intellectual-property, safety, conflict, budget, and civil-and-defensive review.
Conflicts and change triggers
Conflicts: Potential stipend, benefits, laboratory access, investor and corporate networks, public-laboratory reputation, technology and intellectual-property interests, relocation, selection, and the publisher's intended venture require independent review.
What would change this record? Publication of the Cohort 2027 application and eligibility questions, an opening or deadline change, updated stipend or benefit terms, an independent fit memo, or changed intellectual-property, safety, laboratory, conflict, appointment, access, or applicant rules would change this assessment.
Argonne's official application page supports the September 15–October 30, 2026 Cohort 2027 window, 5 p.m. close statement, U.S.-citizen or lawful-permanent-resident rule, preferred technical-founder profile, two-year duration, $115,000 annual stipend plus healthcare, stated non-dilutive support, no-equity statement, and listed priority areas. It does not establish application availability before September 15, a specific person's eligibility, acceptance, adequate funding, facility access, intellectual-property outcome, safety approval, accessibility, relocation, startup success, or relationship.
Indexing and task matching do not establish eligibility, recommendation, availability, funding, provider interest, a relationship, or authorization to apply.
What would change this page?
Publication of the Cohort 2027 application and eligibility questions, an opening or deadline change, updated stipend or benefit terms, an independent fit memo, or changed intellectual-property, safety, laboratory, conflict, appointment, access, or applicant rules would change this assessment.
Potential stipend, benefits, laboratory access, investor and corporate networks, public-laboratory reputation, technology and intellectual-property interests, relocation, selection, and the publisher's intended venture require independent review.
The maintainer intends to explore a commercial venture based on some GShips work. No entity, outside funding, customer, sponsor, or indexed-organization relationship currently exists.